Teitur Trophics Raises EUR 28M in Series A Financing to advance the development and treatment for neurodegenerative diseases

by | Mar 14, 2023

Teitur Trophics (Teitur), a biotech company dedicated to developing new treatments for patients suffering from neurodegenerative diseases, today announces the completion of a 28M Series A financing. The financing was co-led by Sunstone Life Science Ventures and Sound Bioventures, with participation from new investors, Industrifonden, Innovestor’s Life Science Fund and P53 Invest. The proceeds will enable Teitur to progress its lead drug candidate, TT-P34, from candidate selection into clinical development, including a Phase 1b clinical study in neurodegenerative diseases.

Press inquiries should be adressed to:

Søren Lemonius

Managing General Partner